CD24+/CD38- as new prognostic marker for non-small cell lung cancer, Multidisciplinary Respiratory Medicine

Background Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer. Methods In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel. Results We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM. Conclusions We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.

PDF) Targeting G4 motifs of various stem cell makers with designed peptide for therapeutic applications

IJMS, Free Full-Text

Inflammation and tumor progression: signaling pathways and targeted intervention

Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting. - Abstract - Europe PMC

Volume 8, issue 1 Multidisciplinary Respiratory Medicine

Frontiers CD38 Predicts Favorable Prognosis by Enhancing Immune Infiltration and Antitumor Immunity in the Epithelial Ovarian Cancer Microenvironment

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC), BMC Cancer

The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression

Treatment of Stage IV Non-small Cell Lung Cancer

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives, Biomarker Research

WO2016154623A2 - Anti-cd133 monoclonal antibodies and related compositions and methods - Google Patents